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With the availability of new drugs (Directly Acting Anti-
virals, DAA), the ambition to eradicate HCV infection
even in patients infected by “difficult-to-treat” genotypes
is becoming a reality. Benefits are enormous from an
individual and a global perspective since about 3% people
in the world are chronically infected, with a burden of
350,000 deaths related to the long-term complications of
the disease (cirrhosis and hepato-cellular carcinoma).
The lessons we learned from HIV treatment (Highly
Active Antiretroviral Therapy, HAART) are that antivirals
pay-off by saving costs of clinical complications, patients’
stress and sufferance, and an increase in productivity of
the infected individuals can be achieved for the sake of the
society. Moreover, control of HIV replication induced by
HAART can reduce the infection burden in the general
population by decreasing HIV transmissibility [1]. This is
extremely important for infection control when coupled
with behavioural interventions since for HIV (as for HCV)
an effective vaccine is not yet available. So, with highly
active anti-HCV treatments we can now follow in
HAART’s footsteps and even get ahead of HAART cost-
effectiveness because HCV is eradicable and treatment can
be stopped; by contrast, HAART must be continued life-
long with a consequent incremental cost.
However, the road is still long and we should overcome
several obstacles along the way. First, benefits of HCV
treatment are maximal if treatment is prescribed, ideally,
to all patients in need. Unfortunately, HCV epidemic is
largely underground as most HCV infected individuals are
unaware of their infection status. It is clear that screening
policy should be optimized to detect as many cases as pos-
sible but it is unclear what is the most cost-effective
strategy. The article by Zaltron et al., in this supplement
discusses the epidemiological and clinical relevance of
chronic HCV infection, including a review of the screening
strategies and their cost-effectiveness [2]. The US Depart-
ment of Health and Human Services has recently recom-
mended HCV testing for “baby boomers” (i.e., adults born
in the period 1945-65) as well as for adults of any ages
reporting risk factors for HCV infection.
Second, in the current economic crisis, the paradox is
that we should treat as many patients as possible but
resources are limited in nature. Therefore, our focus must
be on improving cost-effectiveness. With this objective in
mind, three main questions for clinicians are: (i) Whom to
treat? (ii) How to treat? (iii) When to treat? The expert-
opinion paper by Petta & Craxì tries to answer to these
questions [3]. For example, these authors underline that,
by considering the initial virological response (Rapid Viro-
logical Response, RVR) and a new pharmacogenomics test
(IL28B genotype) as predictors of treatment success, it is
possible to limit the use of DAA with saving in cost and
drug toxicity. Indeed, a standard treatment with Peg-inter-
feron and ribavirin provides a similar rate of success as a
“triple” regimen including a DAA in 25-33% of patients,
provided that a prognostic score (including pharmacoge-
nomics screening) is favourable and a RVR is achieved. In
their papers, Nucara et al., review the key data on the use
of IL28B genotype in clinical practice [4], while Colucci
describes the molecular tests available as diagnostic tools
and surrogate markers of treatment response [5].
Third, a lesson we learned is the importance of treat-
ment adherence and retention into care [6]. So, clini-
cians should provide the maximum support to improve
patients’ adherence to treatment and increase the rate of
success. A dedicated approach with a strict follow-up
should be in place, not only dealing with adverse events
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and assessing the virological response for a rapid adap-
tation of treatment, but also providing a psychosocial
support to patients in need. Only through an inter-disci-
plinary collaboration following a patient-centred
approach –with clinicians (specialists in infectious dis-
eases, gastroenterology, and hepathology), virologists,
and psychologists working together - we can improve
our standard of care.
Fourth, the holy grail of HCV eradication at the popula-
tion level could be achieved only if HCV transmission is
controlled both with treatment and behavioural interven-
tion. Along this line, it is important to define HCV trans-
mission routes, identify the most-at-risk population and
implement targeted prevention strategies. As appropriately
underlined in the papers by Liberto et al., [7] and by
Ciccozzi et al., [8], monitoring the genetic evolution of
HCV is an essential step to develop efficient preventative
measures for controlling HCV epidemic. Also, epidemiolo-
gic estimates and HCV genotyping will help public health
officials to allocate appropriate health-care resources for
managing this important condition.
What is the way forward? New weapons against HCV
are in the pipeline, allowing the construction of combi-
nation regimens taken orally. Phase 2 trials conducted
in patients naïve to treatment support the efficacy of
these convenient regimens without the addition of
Peg-interferon and ribavirin. In their paper, Puoti et al.,
conclude that the advent of these regimens is eagerly
awaited but caveats in the results of phase 2 trials sug-
gest to dampen enthusiasm and conduct more studies
on how to better use these innovative drugs [9].
Against this background we feel that it is important to
set-up collaborative networks to implement operational
research. The SINERGIE (South Italian Network for
Rational Guidelines and International Epidemiology)
project –object of the last article of the supplement
[10]– will focus on upcoming research questions, with
the final aim of improving the identification, care of
patients, prevention strategies and health resource allo-
cation in the Calabria Region (Southern Italy). This is a
“global”, patient-centred research. We hope that this
project will be extended to other Regions. Indeed, it is
now time for a coordinated, inter-disciplinary effort to
better use the new weapons that we have and those
available in the future. Only with a better knowledge
and understanding we can improve our skills and ability
to fight an insidious enemy such as HCV, driving it to
extinction.
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